Sponsor or institution

Clinical trials and research at Eli Lilly and Company

• 128Clinical trials
• 1New in 30 days
• 62Countries

Newest trials

All recruiting trials (128)

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Abemaciclib in healthy adults: comparing tablet and granule forms to see how they enter the bloodstream

  This study tests different oral forms of abemaciclib in healthy volunteers to see how much and how fast the drug gets into the blood and what side effects occur.

  Recruiting Phase 1 Eli Lilly and Company · Singapore · NCT07818967

• Weekly tirzepatide vs placebo for pediatric obesity (6 to <12 years)

  This study tests whether weekly tirzepatide can help children aged 6 to under 12 with obesity, in addition to healthy lifestyle guidance.

  Recruiting at 2 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 81 other locations · NCT07817875

• Testing LY4329090 in adults with overweight or obesity who are otherwise healthy

  This study tests how LY4329090 works in adults with overweight or obesity who are otherwise healthy to see if it is tolerated and what side effects might occur.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Daytona Beach, Florida and 2 other locations · NCT07808073

• Eloralintide and birth-control pill study in women with overweight or obesity

  This study tests whether eloralintide affects how oral contraceptives work in women with overweight or obesity.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Daytona Beach, Florida and 1 other locations · NCT07808060

• Tirzepatide for type 1 diabetes patients who are overweight or obese

  This study tests whether tirzepatide can affect stomach emptying in adults with type 1 diabetes and overweight or obesity.

  Recruiting Phase 1 Eli Lilly and Company · Miami, Florida · NCT07803744

• Ly5625575: safety and how the body handles the drug in healthy people and those with inflammation

  This study tests LY5625575 in healthy volunteers and in people with elevated C-reactive protein to see if it is safe, well-tolerated, and how it behaves in the body.

  Recruiting Phase 1 Eli Lilly and Company · Miami, Florida and 1 other locations · NCT07801300

• Two Ways of Taking Olomorasib in Healthy Volunteers

  This early-phase study tests two methods of taking olomorasib to see how much and how fast the medicine enters the blood, and to check for side effects in healthy adults.

  Recruiting Phase 1 Eli Lilly and Company · Daytona Beach, Florida · NCT07794592

• Orforglipron in adults with overweight at risk for obesity-related problems

  This study tests whether orforglipron can help people who are overweight and have early signs of metabolic or cardiovascular risk.

  Recruiting at 88 sites Phase 3 Eli Lilly and Company · Anniston, Alabama and 179 other locations · NCT07794579

• Testing LY4405094 in healthy people and people with Alzheimer’s disease

  This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 17 other locations · NCT07787182

• Test of amyloid-targeting medicines in healthy people and adults with Alzheimer’s

  This trial tests the safety and tolerability of amyloid-targeting drugs, plus a placebo, in healthy adults and in people with Alzheimer’s disease to see if the drugs can reduce brain amyloid plaques.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Anaheim, California and 18 other locations · NCT07787169

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Brenipatide added to standard care for adults with major depressive disorder

  This study tests whether brenipatide, given alongside standard care, can help delay the return of depressive symptoms in adults with major depressive disorder.

  Recruiting at 47 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 169 other locations · NCT07775300

• Testing LY4226695 in healthy adults

  This study tests how well LY4226695 is tolerated and how the body handles it in healthy adults.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 1 other locations · NCT07767487

• A first-in-human test of LY4355756 in healthy adults

  This early-phase study tests how LY4355756 behaves in the body and whether it is safe for healthy adults.

  Recruiting Phase 1 Eli Lilly and Company · Dallas, Texas · NCT07765498

• Brenipatide for adults with moderate-to-severe COPD

  This study tests different doses of Brenipatide to see if it is safe and effective for adults with moderate-to-severe COPD, compared with placebo.

  Recruiting at 69 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT07759245

• How Eloralintide Aims to Slow Stomach Emptying in Overweight or Obese Adults

  This study tests whether Eloralintide can slow stomach emptying in adults who are overweight or obese.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · San Antonio, Texas and 1 other locations · NCT07738614

• LY4178256 safety and pharmacokinetics in healthy adults

  This study tests how well LY4178256 is tolerated and how it behaves in the body of healthy adults.

  Recruiting Phase 1 Eli Lilly and Company · Los Alamitos, California and 1 other locations · NCT07698210

• Orforglipron vs. dulaglutide in kids with type 2 diabetes

  This study tests whether orforglipron works and is safe in children and teens with type 2 diabetes, compared with dulaglutide.

  Recruiting at 30 sites Phase 3 Eli Lilly and Company · Sacramento, California and 70 other locations · NCT07668336

• Eloralintide (LY3841136) vs placebo in people who are overweight or obese

  This study tests whether eloralintide can improve insulin sensitivity, metabolism, and body weight compared to placebo in adults who are overweight or obese.

  Recruiting Phase 1 Eli Lilly and Company · Neuss and 1 other locations · NCT07665879

• Blood-level and safety study of LY4174794 in adults who are overweight or obese

  This study tests how safe LY4174794 is and how it behaves in the body of adults who are overweight or obese but otherwise healthy.

  Recruiting Phase 1 Eli Lilly and Company · San Antonio, Texas and 2 other locations · NCT07654972

• Pain relief for knee osteoarthritis: a 2nd phase study of LY4065967 vs placebo

  Researchers are testing whether LY4065967 can help reduce knee pain from osteoarthritis in adults, compared with placebo.

  Recruiting at 36 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 35 other locations · NCT07641517

• Chronic low back pain: test LY4065967 vs. placebo

  This study tests whether LY4065967 is safe and helps reduce chronic low back pain compared to placebo in adults with long‑standing back pain.

  Recruiting at 34 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 35 other locations · NCT07641504

• Orforglipron for Type 2 Diabetes in Ramadan Fasters

  This study tests whether orforglipron helps people with type 2 diabetes who fast during Ramadan, to see if it improves blood sugar control safely.

  Recruiting at 33 sites Phase 3 Eli Lilly and Company · Agra and 39 other locations · NCT07613307

• See if Lepodisiran lowers coronary plaque in people with high Lp(a) and heart disease risk

  This study tests whether lepodisiran can reduce heart-artery plaque in adults with high Lp(a) compared to placebo.

  Recruiting at 53 sites Phase 3 Eli Lilly and Company · La Jolla, California and 56 other locations · NCT07613294

• Breast milk mirikizumab levels in lactating people using mirikizumab for IBS/IBD

  This study tests how much mirikizumab passes into breast milk for people who are breastfeeding while on mirikizumab for an approved condition.

  Recruiting at 2 sites Phase 4 Eli Lilly and Company · Glenview, Illinois and 19 other locations · NCT07612267

• Donanemab follow-up dosing in participants who previously completed TRAILBLAZER-ALZ 3-EXT

  This study tests whether giving annual donanemab doses benefits people with Alzheimer's disease who finished the prior trial.

  Recruiting at 60 sites Phase 3 Eli Lilly and Company · Phoenix, Arizona and 61 other locations · NCT07602582

• Ly3439539 in Alzheimer’s Disease: see if it's safe and affects spinal fluid proteins

  This study tests LY3439539 in adults with Alzheimer’s to see if it changes certain proteins in their spinal fluid over about 9 months.

  Recruiting at 11 sites Phase 1 Eli Lilly and Company · Irvine, California and 15 other locations · NCT07598370

• Weight management with macupatide and eloralintide, alone or together

  This study tests whether macupatide and eloralintide, by themselves or in combination, can help adults who are overweight or have obesity lose weight compared with placebo.

  Recruiting at 40 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 39 other locations · NCT07589608

• Donanemab in Early Cognitive Decline with Lewy Body Features (TRAILBLAZER-ALZ 7)

  This trial tests donanemab versus placebo to see if it can slow thinking and daily-function decline in people with early cognitive decline and Lewy body disease features.

  Recruiting at 47 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 71 other locations · NCT07589595

• ALS master protocol with LY4256984 in eligible completers

  This study tests LY4256984 in people with ALS who completed a parent ALS study, to see if it is safe and tolerable over about 96 weeks.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Leuven and 10 other locations · NCT07571200

• Long-term safety test of LY4256984 in ALS patients

  This long-term extension study will see if LY4256984 is safe and tolerable in people with ALS who completed the earlier trial.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Leuven and 10 other locations · NCT07571174

• Donanemab in Chinese adults at risk for Alzheimer’s decline

  This study tests donanemab versus placebo in Chinese adults who are cognitively unimpaired but show early signs suggesting they may decline due to Alzheimer’s disease.

  Recruiting at 30 sites Phase 3 Eli Lilly and Company · Beijing and 29 other locations · NCT07571161

• Test of LY4302814 in healthy adults

  This study tests how LY4302814 is tolerated and processed in healthy adults to see what side effects might occur.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Daytona Beach, Florida and 1 other locations · NCT07566338

• LY3971297 in heart failure: safety and tolerability in HF with preserved and reduced ejection fraction

  This study tests how well LY3971297 is tolerated and what side effects occur in people with HFpEF or HFrEF.

  Recruiting Phase 1 Eli Lilly and Company · Detroit, Michigan and 11 other locations · NCT07547540

• Brenipatide (LY3537031) for IBS with constipation

  This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.

  Recruiting at 64 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 69 other locations · NCT07545772

• Brenipatide (LY3537031) treatment for adults with IBS‑D

  This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.

  Recruiting at 80 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 88 other locations · NCT07545759

• LY4005130 for adults with non-segmental vitiligo

  This study will test whether intravenous LY4005130 is safe and what side effects it may cause in adults with non-segmental vitiligo.

  Recruiting at 35 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 34 other locations · NCT07533019

• LY4005130 for adults with severe alopecia areata (hair loss)

  This trial tests whether intravenous LY4005130 helps adults with severe alopecia areata regrow scalp hair compared with placebo while monitoring safety and side effects.

  Recruiting at 30 sites Phase 2 Eli Lilly and Company · Fremont, California and 29 other locations · NCT07533006

• LY4515100 for pain after impacted wisdom tooth removal

  This trial will test whether a single oral dose of LY4515100 reduces acute pain after impacted wisdom tooth removal compared with a placebo in adults having two or more third molars removed.

  Recruiting Phase 2 Eli Lilly and Company · Salt Lake City, Utah · NCT07511816

• Flu? No—A combination of an FXR activator and mirikizumab for adults with Crohn's disease

  This study tests whether adding the FXR activator LY4395089 to mirikizumab is better than mirikizumab alone for adults with moderately to severely active Crohn's disease.

  Recruiting at 53 sites Phase 2 Eli Lilly and Company · Scottsdale, Arizona and 70 other locations · NCT07483099

• New treatments for adults with ulcerative colitis or Crohn's disease

  This study tests new treatments for adults with moderately to severely active ulcerative colitis or Crohn's disease to see if they work and are safe.

  Recruiting at 55 sites Phase 2 Eli Lilly and Company · Scottsdale, Arizona and 70 other locations · NCT07483073

• Mirikizumab single versus two under-the-skin injections in healthy adults

  This trial will test if a single injection of mirikizumab solution is as safe and well-tolerated as two subcutaneous injections in healthy adults.

  Recruiting at 5 sites Phase 1 Eli Lilly and Company · Daytona Beach, Florida and 4 other locations · NCT07446101

• Brenipatide added to buprenorphine for people with opioid use disorder

  This will test whether brenipatide, given with buprenorphine (with or without naloxone), is safe and helpful for people with opioid use disorder who still use non-prescribed opioids.

  Recruiting at 54 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 67 other locations · NCT07420283

• Oral LY4268989 for adults with moderate to severe ulcerative colitis.

  This tests whether an oral medicine called LY4268989 helps adults with moderate to severe ulcerative colitis more than a placebo.

  Recruiting at 197 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 257 other locations · NCT07415044

• Brenipatide added to standard antidepressant treatment for adults with major depression

  This trial will see if adding brenipatide to your current antidepressant treatment can delay the return of major depressive symptoms in adults with major depressive disorder.

  Recruiting at 170 sites Phase 3 Eli Lilly and Company · Moorpark, California and 179 other locations · NCT07412756

• Brenipatide added to standard care for adults with schizophrenia

  This will see if adding brenipatide to your usual schizophrenia medication helps more than a placebo plus standard care for adults with schizophrenia.

  Recruiting at 98 sites Phase 2 Eli Lilly and Company · Little Rock, Arkansas and 100 other locations · NCT07410507

• Eloralintide in people with and without liver damage

  This Phase 1 study will test how the medicine eloralintide (LY3841136) is absorbed, processed, and tolerated in adults with healthy livers and in those with mild, moderate, or severe liver damage.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Orlando, Florida and 2 other locations · NCT07401862

• Eloralintide for people with persistent obesity on weekly incretin therapy

  This trial will test whether adding eloralintide helps adults with persistent obesity or overweight who are already taking a weekly incretin medication, with or without type 2 diabetes.

  Recruiting at 135 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 184 other locations · NCT07392190

• Eloralintide for people with obstructive sleep apnea who are overweight or obese

  This study will test whether the drug eloralintide helps adults with moderate-to-severe obstructive sleep apnea who are overweight or obese, whether they use PAP therapy or not.

  Recruiting at 100 sites Phase 3 Eli Lilly and Company · Cullman, Alabama and 114 other locations · NCT07369011

• Eloralintide for knee osteoarthritis pain in adults with overweight or obesity

  This trial tests whether eloralintide reduces knee osteoarthritis pain in adults who are overweight or have obesity.

  Recruiting at 132 sites Phase 3 Eli Lilly and Company · Mobile, Alabama and 146 other locations · NCT07353931

• LY4515100 in healthy adults

  This study will test whether taking LY4515100 by mouth is safe and well tolerated in healthy adults and will measure how the body processes the drug.

  Recruiting Phase 1 Eli Lilly and Company · Dallas, Texas and 1 other locations · NCT07339722

• Eloralintide for weight loss in adults with obesity or overweight without type 2 diabetes

  This trial tests whether eloralintide helps adults with obesity or overweight (who do not have type 2 diabetes) lose weight and is safe.

  Recruiting at 128 sites Phase 3 Eli Lilly and Company · Tuscaloosa, Alabama and 157 other locations · NCT07321886

• Imlunestrant in Premenopausal ER+ HER2- Early Breast Cancer

  This study tests imlunestrant in premenopausal women with ER+ HER2- early breast cancer to see how it works with or without ovarian suppression compared to tamoxifen.

  Recruiting at 25 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 89 other locations · NCT07287098

• Brenipatide for adults with bipolar disorder (RENEW-Bipolar-1)

  This trial will test whether adding brenipatide to standard bipolar medications can delay worsening of symptoms in adults with bipolar I or II.

  Recruiting at 84 sites Phase 2 Eli Lilly and Company · Orange, California and 86 other locations · NCT07286175

• LY4065967 for diabetic peripheral neuropathic pain (part of a chronic pain master protocol)

  This trial tests whether LY4065967 can safely reduce pain in adults with diabetic peripheral neuropathic pain.

  Recruiting at 36 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 35 other locations · NCT07285018

• Eloralintide for weight loss in adults with overweight or obesity and type 2 diabetes

  This study will test whether eloralintide helps adults with overweight or obesity and type 2 diabetes lose more weight than a placebo over about 75 weeks.

  Recruiting at 117 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 142 other locations · NCT07282600

• LY4298445 in healthy adults and people with lupus or rheumatoid arthritis

  This trial will test whether LY4298445 is safe and well tolerated in healthy adults and in people with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · Brisbane and 9 other locations · NCT07276958

• Solbinsiran injections to lower very high triglycerides

  This trial will test whether two injections of solbinsiran can lower very high triglyceride levels in adults with severe hypertriglyceridemia.

  Recruiting at 6 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 40 other locations · NCT07269210

• LY4213663 in healthy people and people with rheumatoid arthritis

  This will test whether LY4213663 is safe and how the body handles it in healthy volunteers and people with rheumatoid arthritis.

  Recruiting at 9 sites Phase 1 Eli Lilly and Company · Anniston, Alabama and 9 other locations · NCT07258849

• PET imaging with [18F]LY4214835 in adults with cancer and healthy volunteers

  This research will test a single IV injection of [18F]LY4214835 in adults with cancer and in healthy volunteers to see if it is safe and well tolerated.

  Recruiting at 2 sites Phase 1 Eli Lilly and Company · New Haven, Connecticut and 5 other locations · NCT07258836

• Eye scan to detect Alzheimer’s related protein deposits in adults with memory issues

  A screening eye test is being tried in adults with memory problems to see if retinal changes can signal Alzheimer’s-related protein deposits.

  Recruiting at 2 sites Eli Lilly and Company · Abu Dhabi and 2 other locations · NCT07254234

• Tirzepatide versus usual care for adults with obesity (no diabetes) in UK primary care

  This study will test whether tirzepatide helps adults with obesity who do not have diabetes lose weight and lower their chance of developing type 2 diabetes compared with standard care in UK primary care.

  Recruiting at 12 sites Phase 4 Eli Lilly and Company · Altrincham and 29 other locations · NCT07247084

• Orforglipron to lower cardiovascular events in adults with atherosclerotic cardiovascular disease or chronic kidney disease (ATTAIN-Outcomes)

  This trial tests whether orforglipron reduces heart-related events compared with placebo in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease.

  Recruiting at 512 sites Phase 3 Eli Lilly and Company · Bahía Blanca and 565 other locations · NCT07241390

• LY4584180 with rituximab for adults with previously treated B‑cell lymphomas

  This trial will test LY4584180 together with rituximab in adults with previously treated B‑cell lymphomas to see if it is safe, reaches useful levels in the blood, and can help control the disease.

  Recruiting at 21 sites Phase 1 Eli Lilly and Company · Scottsdale, Arizona and 45 other locations · NCT07226843

• Brenipatide to help adults who recently quit smoking avoid relapse

  This trial will see if brenipatide helps adults who recently quit smoking stay off cigarettes better than a placebo.

  Recruiting at 28 sites Phase 2 Eli Lilly and Company · Rogers, Arkansas and 28 other locations · NCT07223840

• Orforglipron for peripheral artery disease with intermittent claudication

  This trial will test whether taking orforglipron once daily helps people with Fontaine II peripheral artery disease (intermittent claudication) and is safe.

  Recruiting at 142 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 168 other locations · NCT07223593

• Baricitinib to preserve insulin-producing beta cells in people newly diagnosed with type 1 diabetes

  This trial will test whether the drug baricitinib can help preserve insulin-producing beta cells in children and adults who were recently diagnosed with type 1 diabetes.

  Recruiting at 108 sites Phase 3 Eli Lilly and Company · Aurora, Colorado and 129 other locations · NCT07222332

• Baricitinib to delay the start of clinical (Stage 3) type 1 diabetes in at‑risk children and adults

  This will test whether the medicine baricitinib can delay the start of clinical type 1 diabetes in children and adults who are at high risk.

  Recruiting at 95 sites Phase 3 Eli Lilly and Company · Santa Barbara, California and 111 other locations · NCT07222137

• Brenipatide for moderate-to-severe alcohol use disorder

  This trial will test whether brenipatide is safe and helps adults with moderate-to-severe alcohol use disorder who want to stop or cut down drinking.

  Recruiting at 4 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 116 other locations · NCT07219966

• Brenipatide treatment for people with alcohol use disorder

  This trial will see if brenipatide helps adults with alcohol use disorder reduce drinking and is safe compared with a placebo.

  Recruiting at 54 sites Phase 3 Eli Lilly and Company · Scottsdale, Arizona and 114 other locations · NCT07219953

• Brenipatide versus placebo for adults with uncontrolled moderate-to-severe asthma

  This trial tests whether different doses of brenipatide can safely improve asthma control and reduce severe attacks in adults with uncontrolled moderate-to-severe asthma.

  Recruiting at 112 sites Phase 2 Eli Lilly and Company · Tempe, Arizona and 119 other locations · NCT07219173

• Vepugratinib with enfortumab vedotin and pembrolizumab for FGFR3‑altered advanced urothelial cancer

  This trial tests whether adding vepugratinib to enfortumab vedotin and pembrolizumab helps people with advanced or metastatic urothelial (bladder) cancer who have an FGFR3 genetic change, compared with placebo.

  Recruiting at 129 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 275 other locations · NCT07218380

• Long-term pirtobrutinib treatment for people with previously treated CLL/SLL

  This trial will test whether taking pirtobrutinib long-term is safe for people who have already been treated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  Recruiting at 22 sites Phase 4 Eli Lilly and Company · Mobile, Alabama and 49 other locations · NCT07218341

• Sofetabart Mipitecan (LY4170156) versus standard chemotherapy for platinum-resistant and platinum-sensitive high-grade ovarian, fallopian tube, and primary peritoneal cancer

  This trial tests whether the targeted drug Sofetabart Mipitecan can better shrink tumors or delay progression than standard chemotherapies for people with platinum-resistant or platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 212 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 263 other locations · NCT07213804

• LY4337713 for people with FAP-positive ovarian, breast, pancreatic, colorectal, or esophageal cancers

  This trial tests LY4337713, a FAP-targeted lutetium-177 therapy, in people with advanced cancers that show high levels of fibroblast activation protein (FAP).

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Newport Beach, California and 29 other locations · NCT07213791

• Orforglipron for women with stress urinary incontinence who are overweight or have obesity

  This trial will test whether orforglipron reduces urine leakage in adult women with stress urinary incontinence who are overweight or have obesity.

  Recruiting at 104 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 119 other locations · NCT07202884

• LY4268989 (MORF-057) with mirikizumab for adults with moderate-to-severe ulcerative colitis

  We will test whether adding LY4268989 to mirikizumab helps adults with moderate-to-severe ulcerative colitis get better control than mirikizumab alone.

  Recruiting at 136 sites Phase 2 Eli Lilly and Company · Scottsdale, Arizona and 146 other locations · NCT07186101

• Tersolisib plus standard anti-cancer medicines for advanced HR+/HER2- breast cancer with a PIK3CA change

  This trial tests whether adding tersolisib to standard first-line anti-cancer medicines helps people with advanced hormone receptor–positive, HER2‑negative breast cancer that has a PIK3CA mutation.

  Recruiting at 179 sites Phase 3 Eli Lilly and Company · Anchorage, Alaska and 363 other locations · NCT07174336

• LY3537021 for preventing chemo-related nausea and vomiting in adults

  This trial will test whether adding LY3537021 to standard anti-nausea care helps prevent nausea and vomiting in adults starting AC or high-dose cisplatin chemotherapy.

  Recruiting at 58 sites Phase 2 Eli Lilly and Company · Greenbrae, California and 66 other locations · NCT07169851

• Testing retatrutide and tirzepatide to prevent serious liver complications in adults with high‑risk MASLD

  This trial tests whether retatrutide or tirzepatide can prevent major liver complications in adults with high‑risk metabolic dysfunction‑associated steatotic liver disease identified by noninvasive tests.

  Recruiting at 502 sites Phase 3 Eli Lilly and Company · Tuscaloosa, Alabama and 562 other locations · NCT07165028

• How LY3537031 is processed and tolerated in people with normal or impaired liver function

  This trial will test how LY3537031 is absorbed, distributed, and cleared and whether it is safe when given under the skin to adults with normal liver function and to adults with mild, moderate, or severe liver impairment.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Kistarcsa and 2 other locations · NCT07165002

• Muvalaplin to lower major heart and stroke events in adults with high lipoprotein(a)

  This study tests whether muvalaplin can lower the chance of heart attack, stroke, or other major cardiovascular events in adults with high lipoprotein(a) who have or are at risk for cardiovascular disease.

  Recruiting at 716 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 803 other locations · NCT07157774

• Tracking blood P-tau217 and early cognitive change in people without memory symptoms

  This project will test whether yearly blood P-tau217 tests can identify people who currently have no memory symptoms but later show cognitive worsening.

  Recruiting at 4 sites Phase 3 Eli Lilly and Company · Houston, Texas and 3 other locations · NCT07142954

• Using a p‑tau217 blood test to guide early evaluation and care for people with memory complaints

  This study will test whether giving clinicians p‑tau217 blood test results changes how they manage patients over 50 who come in with memory or cognitive complaints.

  Recruiting Eli Lilly and Company · New York, New York · NCT07140744

• LY4257496 for GRPR-positive advanced breast, colorectal, prostate, and endometrial cancer (OMNIRAY)

  This Phase 1 test tries LY4257496, with GRPR imaging using LY4257529 and sometimes standard treatments, to see if it is safe and helps people with GRPR-positive advanced breast, colorectal, prostate, or endometrial cancer.

  Recruiting at 15 sites Phase 1 Eli Lilly and Company · Duarte, California and 32 other locations · NCT07114601

• New therapy dose test for people with prior B-cell cancers

  This early-phase study tests different doses of LY4152199 to see if it is safe and effective for people who have already been treated for certain B-cell lymphomas.

  Recruiting at 25 sites Phase 1 Eli Lilly and Company · Duarte, California and 50 other locations · NCT07101328

• LY4256984 for people with sporadic ALS.

  This trial will test LY4256984 given into the spine to see how safe it is and how it behaves in the body for people with sporadic ALS.

  Recruiting at 10 sites Phase 1 Eli Lilly and Company · Leuven and 11 other locations · NCT07100119

• LY4088044 in healthy volunteers

  This trial will test how LY4088044 is tolerated and cleared from the body when given under the skin or into a vein in healthy adults.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Los Alamitos, California and 5 other locations · NCT07090785

• LY4175408 for selected advanced lung, endometrial, and triple‑negative breast cancers

  This trial tests an experimental drug called LY4175408 to see if it is safe and works for people with advanced or metastatic non‑small cell or small cell lung cancer, endometrial cancer, or triple‑negative breast cancer.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Stanford, California and 26 other locations · NCT07046923

• Testing the safety and body distribution of LY4066708 in healthy adults

  This tests LY4066708 in healthy adults to see if it is safe and how much reaches the blood and central nervous system over up to 24 weeks.

  Recruiting Phase 1 Eli Lilly and Company · Holbeck, Leeds · NCT07046559

• Evaluating LY4057996 in Healthy Individuals and Those with Type 1 and Type 2 Diabetes

  This study is testing a new drug called LY4057996 to see how well it is tolerated and what side effects it might have in healthy people and those with Type 1 or Type 2 diabetes.

  Recruiting Phase 1 Eli Lilly and Company · Neuss · NCT06945406

• Mirikizumab with or without tirzepatide for adults with moderately to severely active Crohn's disease who are overweight or have obesity

  This trial tests whether adding tirzepatide to mirikizumab helps adults with moderately to severely active Crohn's disease who are overweight or have obesity.

  Recruiting at 174 sites Phase 3 Eli Lilly and Company · Dothan, Alabama and 182 other locations · NCT06937099

• Mirikizumab given at the same time as tirzepatide for adults with moderate-to-severe ulcerative colitis who are overweight or have obesity

  This will test whether giving mirikizumab together with tirzepatide helps adults with moderate-to-severe ulcerative colitis who are overweight or obese reduce UC symptoms and lose at least 10% of their body weight.

  Recruiting at 179 sites Phase 3 Eli Lilly and Company · Dothan, Alabama and 185 other locations · NCT06937086

• Comparing LY3457263 to placebo for type 2 diabetes patients on semaglutide or tirzepatide

  This study is testing if a new medication called LY3457263 can help people with type 2 diabetes who are already using semaglutide or tirzepatide lower their blood sugar levels better than a placebo.

  Recruiting at 55 sites Phase 2 Eli Lilly and Company · Phoenix, Arizona and 59 other locations · NCT06897475

• Combining Olomorasib with Standard Treatments for KRAS G12C-mutant Lung Cancer

  This study is testing if adding olomorasib to standard treatments can help people with KRAS G12C-mutant lung cancer do better than with the usual care alone.

  Recruiting at 349 sites Phase 3 Eli Lilly and Company · Huntsville, Alabama and 367 other locations · NCT06890598

• Long-term pirtobrutinib continuation for people with previously treated CLL/SLL or non-Hodgkin lymphoma

  People who are already taking pirtobrutinib in an earlier trial can continue the drug or their follow-up visits so doctors can see if it stays safe and keeps helping over the long term.

  Recruiting at 25 sites Phase 4 Eli Lilly and Company · Miami, Florida and 35 other locations · NCT06876662

• Long-term safety follow-up of pirtobrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma

  This program lets people who previously received pirtobrutinib in a Lilly study continue treatment or follow-up so doctors can see if the drug remains safe over the long term.

  Recruiting at 32 sites Phase 4 Eli Lilly and Company · Jacksonville, Florida and 37 other locations · NCT06876649

• Investigating the effectiveness of tirzepatide added to ixekizumab for psoriasis and obesity

  This study is testing if adding a weight-loss medication called tirzepatide to an existing psoriasis treatment can help people with moderate-to-severe plaque psoriasis who are also overweight or obese.

  Recruiting at 38 sites Phase 4 Eli Lilly and Company · Phoenix, Arizona and 37 other locations · NCT06857942

• Testing VTX2735 for treating recurrent pericarditis

  This study is testing a new drug called VTX2735 to see if it can help people with recurrent pericarditis feel better and reduce their symptoms.

  Recruiting at 18 sites Phase 2 Eli Lilly and Company · La Jolla, California and 19 other locations · NCT06836232

• Evaluating LY4006896 in Healthy Individuals and Those with Parkinson's Disease

  This study is testing a new drug called LY4006896 to see if it's safe and how it works in both healthy people and those with Parkinson's disease.

  Recruiting at 11 sites Phase 1 Eli Lilly and Company · Los Alamitos, California and 13 other locations · NCT06809400

• Evaluating dulaglutide dosing in children with Type 2 diabetes

  This study is testing different doses of dulaglutide to see how well it helps children with Type 2 diabetes who are already using diet and other medications.

  Recruiting at 44 sites Phase 3 Eli Lilly and Company · Tucson, Arizona and 50 other locations · NCT06739122

• Pirtobrutinib for adults with primary immune thrombocytopenia

  This trial tests whether oral pirtobrutinib can help adults with relapsed or treatment‑resistant primary immune thrombocytopenia (ITP) raise platelet counts and reduce bleeding risk.

  Recruiting at 39 sites Phase 1/2 Eli Lilly and Company · Los Angeles, California and 42 other locations · NCT06721013

• Evaluating Orforglipron for Adolescents with Obesity or Overweight

  This study is testing if an oral medication called orforglipron can help adolescents who are overweight or obese improve their weight and health over 18 months.

  Recruiting at 8 sites Phase 3 Eli Lilly and Company · Oxnard, California and 33 other locations · NCT06672939

• A trial for treating obesity in children and adolescents

  This study is testing different medications to see if they can help kids and teens aged 12 to 17 who struggle with obesity and have tried to lose weight before.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 116 other locations · NCT06672549

• Evaluating LY4006895 in Healthy Individuals and Those with Early Alzheimer's Disease

  This study is testing a new drug called LY4006895 to see if it's safe for healthy people and those with early Alzheimer's disease.

  Recruiting at 6 sites Phase 1 Eli Lilly and Company · Los Alamitos, California and 12 other locations · NCT06657768

• Evaluating Pirtobrutinib for patients with relapsed or refractory CLL/SLL

  This study is testing a new medication called Pirtobrutinib to see if it helps people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma feel better after they’ve already tried other treatments.

  Recruiting at 125 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 128 other locations · NCT06588478

• Comparing Donanemab with Usual Care for Early Alzheimer's Disease

  This study is testing if adding donanemab to regular care can help people with early Alzheimer's disease feel better over time compared to just sticking with usual care.

  Recruiting Eli Lilly and Company · Huntsville, Alabama · NCT06566170

• Gene therapy for vestibular schwannoma treatment

  This study is testing a new gene therapy to see if it can safely help people with growing vestibular schwannomas and severe hearing loss.

  Recruiting at 4 sites Phase 1/2 Eli Lilly and Company · Baltimore, Maryland and 3 other locations · NCT06517888

• LY4052031 for advanced or metastatic urothelial and other nectin‑4–expressing solid tumors

  This trial will test whether LY4052031 is safe and can help people with advanced or metastatic urothelial cancer or other solid tumors that express nectin‑4.

  Recruiting at 36 sites Phase 1 Eli Lilly and Company · Duarte, California and 39 other locations · NCT06465069

• Evaluating tirzepatide for treating obesity in adolescents

  This study is testing if tirzepatide can help teenagers with obesity lose weight and improve their heart health while they follow a healthy eating and exercise program.

  Recruiting Phase 3 Eli Lilly and Company · Los Angeles, California and 68 other locations · NCT06439277

• Evaluating LY4170156 for advanced solid tumors

  This study is testing a new drug called LY4170156 to see if it is safe and effective for people with advanced solid tumors like ovarian and lung cancers.

  Recruiting at 24 sites Phase 1 Eli Lilly and Company · Scottsdale, Arizona and 24 other locations · NCT06400472

• Testing a new drug for patients with myelofibrosis who didn't respond to previous treatments

  This study is testing a new drug for people with myelofibrosis who haven't had success with previous treatments to see if it’s safe and effective.

  Recruiting at 17 sites Phase 1 Eli Lilly and Company · Palo Alto, California and 20 other locations · NCT06343805

• Evaluating lebrikizumab for chronic rhinosinusitis with nasal polyps

  This study is testing a new drug called lebrikizumab to see if it can help adults with chronic rhinosinusitis and nasal polyps feel better while they are already using nasal sprays.

  Recruiting at 176 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 201 other locations · NCT06338995

• Testing LY3954068 for early Alzheimer's disease

  This study is testing a new drug called LY3954068 to see if it is safe and how it works in people with early Alzheimer's disease.

  Recruiting at 9 sites Phase 1 Eli Lilly and Company · Maitland, Florida and 9 other locations · NCT06297590

• Evaluating MORF-057 for treating active Crohn's disease in adults

  This study is testing a new medication called MORF-057 to see if it can help adults with moderately to severely active Crohn's disease who haven't had enough relief from other treatments.

  Recruiting at 175 sites Phase 2 Eli Lilly and Company · Lancaster, California and 223 other locations · NCT06226883

• Evaluating interventions for managing obesity and overweight

  This study is testing different new treatments to see if they can help people with obesity and overweight manage their weight safely and effectively.

  Recruiting at 47 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 56 other locations · NCT06143956

• Combining Olomorasib and Pembrolizumab for Advanced KRAS G12C-Mutant Lung Cancer

  This study is testing if a new drug combined with Pembrolizumab can help people with advanced lung cancer that has a specific genetic mutation feel better and live longer compared to standard treatments.

  Recruiting at 413 sites Phase 3 Eli Lilly and Company · Huntsville, Alabama and 414 other locations · NCT06119581

• A master protocol for testing cancer drugs in children and young adults

  This study is trying out different cancer drugs to see how well they work for children and young adults with cancer, using a flexible approach that allows for new treatments to be added as they become available.

  Recruiting at 52 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 71 other locations · NCT05999994

• Comparing different treatments for chronic pain conditions

  This study is testing different treatments for chronic pain conditions like osteoarthritis and diabetic neuropathy to see which ones work better than a placebo.

  Recruiting at 36 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 63 other locations · NCT05986292

• Gene therapy for hearing loss caused by otoferlin gene mutations

  This study is testing a new gene therapy to see if it can help restore hearing in people with severe hearing loss caused by mutations in the otoferlin gene.

  Recruiting at 3 sites Phase 3 Eli Lilly and Company · San Francisco, California and 8 other locations · NCT05821959

• Testing STX-478 for advanced solid tumors and breast cancer

  This study is testing a new cancer drug called STX-478 to see if it can help people with advanced solid tumors and breast cancer, both on its own and when used with other treatments.

  Recruiting at 59 sites Phase 1/2 Eli Lilly and Company · Los Angeles, California and 64 other locations · NCT05768139

• Treatment of severe alopecia areata in children using baricitinib

  This study is testing if the medication baricitinib can help children aged 6 to under 18 with severe alopecia areata by seeing how well it works and if it’s safe over a long period.

  Recruiting at 99 sites Phase 3 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT05723198

• Evaluating LOXO-435 for treating cancer with FGFR3 gene changes

  This study is testing a new cancer drug called LOXO-435 to see if it can safely help people with advanced tumors that have changes in the FGFR3 gene, either on its own or with standard treatments.

  Recruiting at 82 sites Phase 1 Eli Lilly and Company · Tucson, Arizona and 82 other locations · NCT05614739

• Evaluating Mirikizumab for Children with Crohn's Disease

  This study is testing a new medication called mirikizumab to see if it helps children with Crohn's disease feel better and manage their symptoms.

  Recruiting at 71 sites Phase 3 Eli Lilly and Company · Los Angeles, California and 80 other locations · NCT05509777

• Pirtobrutinib versus ibrutinib for people with CLL or SLL.

  This trial will test whether pirtobrutinib works better or is safer than ibrutinib for adults with CLL/SLL, with a separate part that tries pirtobrutinib alone in treatment‑naïve patients who have a 17p deletion.

  Recruiting at 93 sites Phase 3 Eli Lilly and Company · Anaheim, California and 142 other locations · NCT05254743

• Evaluating Mirikizumab for Children with Ulcerative Colitis or Crohn's Disease

  This study is testing if a medication called mirikizumab can help children with ulcerative colitis or Crohn's disease feel better over a long period of time.

  Recruiting at 39 sites Phase 3 Eli Lilly and Company · San Francisco, California and 68 other locations · NCT04844606

• Evaluating baricitinib for treating juvenile idiopathic arthritis in children

  This study tests if continuing treatment with baricitinib helps children with juvenile idiopathic arthritis feel better and stay safe.

  Recruiting at 46 sites Phase 3 Eli Lilly and Company · Rosario and 76 other locations · NCT03773965

Quick answers

How many clinical trials run by Eli Lilly and Company are recruiting right now?

128, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 62 countries. The most sites are in United States (112 trials), Japan (68 trials), Germany (52 trials), Spain (51 trials), China (51 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 43, Phase 1: 42, Phase 2: 31, Phase 4: 6. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →